Benzinga | Aug 5, 2021 06:33AM EDT

Regeneron Pharmaceuticals Q2 Adj. EPS $25.80 Beats $17.69 Estimate, Sales $5.14B Beat $3.89B Estimate

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $25.80 per share which beat the analyst consensus estimate of $17.69 by 45.85 percent. This is a 260.34 percent increase over earnings of $7.16 per share from the same period last year. The company reported quarterly sales of $5.14 billion which beat the analyst consensus estimate of $3.89 billion by 32.13 percent. This is a 163.32 percent increase over sales of $1.95 billion the same period last year.